Description
Panitumumab is a fully human monoclonal antibody used to treat metastatic colorectal cancer in patients whose tumors do not have KRAS gene mutations. It is typically reserved for patients whose cancer has progressed despite other treatments.
Mechanism of Action
It works by binding to and blocking the epidermal growth factor receptor (EGFR) on cancer cells, preventing signals that promote tumor growth and proliferation.
Side Effects
Severe skin reactions and rash
Diarrhea
Fatigue
Hypomagnesemia (low magnesium levels)
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06011772
Early med_phase_prefix1
Active, not recruiting
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
United States